ChloroquineV1, PubMed, Checkpoint, bibRecord, 000115

Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioleiomyomatosis.

Identifieur interne : 000115 ( PubMed/Checkpoint ); précédent : 000114; suivant : 000116

Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioleiomyomatosis.

Auteurs : Anthony M. Lamattina [États-Unis] ; Angelo Taveira-Dasilva [États-Unis] ; Hilary J. Goldberg [États-Unis] ; Shefali Bagwe [États-Unis] ; Ye Cui [États-Unis] ; Ivan O. Rosas [États-Unis] ; Joel Moss [États-Unis] ; Elizabeth P. Henske [États-Unis] ; Souheil El-Chemaly [États-Unis]

Source :

Chest [ 1931-3543 ] ; 2018.

RBID : pubmed:30144422

Descripteurs français

KwdFr :
- Acetyl-coA carboxylase (sang), Adulte, Antienzymes (administration et posologie), Association de médicaments (), Femelle, Fibrinogène (analyse), Humains, Hydroxychloroquine (administration et posologie), Hydroxychloroquine (effets indésirables), Immunosuppresseurs (administration et posologie), Immunosuppresseurs (effets indésirables), Lymphangioléiomyomatose (diagnostic), Lymphangioléiomyomatose (sang), Lymphangioléiomyomatose (traitement médicamenteux), Maladies pulmonaires (diagnostic), Maladies pulmonaires (sang), Maladies pulmonaires (traitement médicamenteux), Marqueurs biologiques (analyse), Marqueurs biologiques (sang), Récepteur-3 au facteur croissance endothéliale vasculaire (sang), Sirolimus (administration et posologie), Sirolimus (effets indésirables), Surveillance pharmacologique (), Tests de la fonction respiratoire ().
MESH :
- administration et posologie : Antienzymes, Hydroxychloroquine, Immunosuppresseurs, Sirolimus.
- analyse : Fibrinogène, Marqueurs biologiques.
- diagnostic : Lymphangioléiomyomatose, Maladies pulmonaires.
- effets indésirables : Hydroxychloroquine, Immunosuppresseurs, Sirolimus.
- sang : Acetyl-coA carboxylase, Lymphangioléiomyomatose, Maladies pulmonaires, Marqueurs biologiques, Récepteur-3 au facteur croissance endothéliale vasculaire.
- traitement médicamenteux : Lymphangioléiomyomatose, Maladies pulmonaires.
- Adulte, Association de médicaments, Femelle, Humains, Surveillance pharmacologique, Tests de la fonction respiratoire.

English descriptors

KwdEn :
- Acetyl-CoA Carboxylase (blood), Adult, Biomarkers (analysis), Biomarkers (blood), Correlation of Data, Drug Monitoring (methods), Drug Therapy, Combination (methods), Enzyme Inhibitors (administration & dosage), Female, Fibrinogen (analysis), Humans, Hydroxychloroquine (administration & dosage), Hydroxychloroquine (adverse effects), Immunosuppressive Agents (administration & dosage), Immunosuppressive Agents (adverse effects), Lung Diseases (blood), Lung Diseases (diagnosis), Lung Diseases (drug therapy), Lymphangioleiomyomatosis (blood), Lymphangioleiomyomatosis (diagnosis), Lymphangioleiomyomatosis (drug therapy), Respiratory Function Tests (methods), Sirolimus (administration & dosage), Sirolimus (adverse effects), Vascular Endothelial Growth Factor Receptor-3 (blood).
MESH :
- chemical , administration & dosage : Enzyme Inhibitors, Hydroxychloroquine, Immunosuppressive Agents, Sirolimus.
- chemical , adverse effects : Hydroxychloroquine, Immunosuppressive Agents, Sirolimus.
- chemical , analysis : Biomarkers, Fibrinogen.
- chemical , blood : Acetyl-CoA Carboxylase, Biomarkers, Vascular Endothelial Growth Factor Receptor-3.
- blood : Lung Diseases, Lymphangioleiomyomatosis.
- diagnosis : Lung Diseases, Lymphangioleiomyomatosis.
- drug therapy : Lung Diseases, Lymphangioleiomyomatosis.
- methods : Drug Monitoring, Drug Therapy, Combination, Respiratory Function Tests.
- Adult, Correlation of Data, Female, Humans.

Abstract

We have previously conducted the Sirolimus and Autophagy Inhibition in LAM (SAIL) trial, a phase 1 dose-escalation study of the combination of sirolimus and hydroxychloroquine in patients with lymphangioleiomyomatosis (LAM). The goal of the present study was to analyze sera from the SAIL trial to identify novel biomarkers that could shed light into disease pathogenesis and response to therapy.

DOI: 10.1016/j.chest.2018.08.1029
PubMed: 30144422

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 000089
to stream PubMed, to step Curation: 000089

Links to Exploration step

pubmed:30144422

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioleiomyomatosis.</title>
<author><name sortKey="Lamattina, Anthony M" sort="Lamattina, Anthony M" uniqKey="Lamattina A" first="Anthony M" last="Lamattina">Anthony M. Lamattina</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Taveira Dasilva, Angelo" sort="Taveira Dasilva, Angelo" uniqKey="Taveira Dasilva A" first="Angelo" last="Taveira-Dasilva">Angelo Taveira-Dasilva</name>
<affiliation wicri:level="2"><nlm:affiliation>Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
<wicri:cityArea>Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Goldberg, Hilary J" sort="Goldberg, Hilary J" uniqKey="Goldberg H" first="Hilary J" last="Goldberg">Hilary J. Goldberg</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Bagwe, Shefali" sort="Bagwe, Shefali" uniqKey="Bagwe S" first="Shefali" last="Bagwe">Shefali Bagwe</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Cui, Ye" sort="Cui, Ye" uniqKey="Cui Y" first="Ye" last="Cui">Ye Cui</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Rosas, Ivan O" sort="Rosas, Ivan O" uniqKey="Rosas I" first="Ivan O" last="Rosas">Ivan O. Rosas</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Moss, Joel" sort="Moss, Joel" uniqKey="Moss J" first="Joel" last="Moss">Joel Moss</name>
<affiliation wicri:level="2"><nlm:affiliation>Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
<wicri:cityArea>Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Henske, Elizabeth P" sort="Henske, Elizabeth P" uniqKey="Henske E" first="Elizabeth P" last="Henske">Elizabeth P. Henske</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="El Chemaly, Souheil" sort="El Chemaly, Souheil" uniqKey="El Chemaly S" first="Souheil" last="El-Chemaly">Souheil El-Chemaly</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Electronic address: sel-chemaly@partners.org.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston</wicri:cityArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2018">2018</date>
<idno type="RBID">pubmed:30144422</idno>
<idno type="pmid">30144422</idno>
<idno type="doi">10.1016/j.chest.2018.08.1029</idno>
<idno type="wicri:Area/PubMed/Corpus">000089</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000089</idno>
<idno type="wicri:Area/PubMed/Curation">000089</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000089</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000115</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000115</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioleiomyomatosis.</title>
<author><name sortKey="Lamattina, Anthony M" sort="Lamattina, Anthony M" uniqKey="Lamattina A" first="Anthony M" last="Lamattina">Anthony M. Lamattina</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Taveira Dasilva, Angelo" sort="Taveira Dasilva, Angelo" uniqKey="Taveira Dasilva A" first="Angelo" last="Taveira-Dasilva">Angelo Taveira-Dasilva</name>
<affiliation wicri:level="2"><nlm:affiliation>Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
<wicri:cityArea>Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Goldberg, Hilary J" sort="Goldberg, Hilary J" uniqKey="Goldberg H" first="Hilary J" last="Goldberg">Hilary J. Goldberg</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Bagwe, Shefali" sort="Bagwe, Shefali" uniqKey="Bagwe S" first="Shefali" last="Bagwe">Shefali Bagwe</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Cui, Ye" sort="Cui, Ye" uniqKey="Cui Y" first="Ye" last="Cui">Ye Cui</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Rosas, Ivan O" sort="Rosas, Ivan O" uniqKey="Rosas I" first="Ivan O" last="Rosas">Ivan O. Rosas</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Moss, Joel" sort="Moss, Joel" uniqKey="Moss J" first="Joel" last="Moss">Joel Moss</name>
<affiliation wicri:level="2"><nlm:affiliation>Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
<wicri:cityArea>Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Henske, Elizabeth P" sort="Henske, Elizabeth P" uniqKey="Henske E" first="Elizabeth P" last="Henske">Elizabeth P. Henske</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="El Chemaly, Souheil" sort="El Chemaly, Souheil" uniqKey="El Chemaly S" first="Souheil" last="El-Chemaly">Souheil El-Chemaly</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Electronic address: sel-chemaly@partners.org.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston</wicri:cityArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Chest</title>
<idno type="eISSN">1931-3543</idno>
<imprint><date when="2018" type="published">2018</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acetyl-CoA Carboxylase (blood)</term>
<term>Adult</term>
<term>Biomarkers (analysis)</term>
<term>Biomarkers (blood)</term>
<term>Correlation of Data</term>
<term>Drug Monitoring (methods)</term>
<term>Drug Therapy, Combination (methods)</term>
<term>Enzyme Inhibitors (administration & dosage)</term>
<term>Female</term>
<term>Fibrinogen (analysis)</term>
<term>Humans</term>
<term>Hydroxychloroquine (administration & dosage)</term>
<term>Hydroxychloroquine (adverse effects)</term>
<term>Immunosuppressive Agents (administration & dosage)</term>
<term>Immunosuppressive Agents (adverse effects)</term>
<term>Lung Diseases (blood)</term>
<term>Lung Diseases (diagnosis)</term>
<term>Lung Diseases (drug therapy)</term>
<term>Lymphangioleiomyomatosis (blood)</term>
<term>Lymphangioleiomyomatosis (diagnosis)</term>
<term>Lymphangioleiomyomatosis (drug therapy)</term>
<term>Respiratory Function Tests (methods)</term>
<term>Sirolimus (administration & dosage)</term>
<term>Sirolimus (adverse effects)</term>
<term>Vascular Endothelial Growth Factor Receptor-3 (blood)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Acetyl-coA carboxylase (sang)</term>
<term>Adulte</term>
<term>Antienzymes (administration et posologie)</term>
<term>Association de médicaments ()</term>
<term>Femelle</term>
<term>Fibrinogène (analyse)</term>
<term>Humains</term>
<term>Hydroxychloroquine (administration et posologie)</term>
<term>Hydroxychloroquine (effets indésirables)</term>
<term>Immunosuppresseurs (administration et posologie)</term>
<term>Immunosuppresseurs (effets indésirables)</term>
<term>Lymphangioléiomyomatose (diagnostic)</term>
<term>Lymphangioléiomyomatose (sang)</term>
<term>Lymphangioléiomyomatose (traitement médicamenteux)</term>
<term>Maladies pulmonaires (diagnostic)</term>
<term>Maladies pulmonaires (sang)</term>
<term>Maladies pulmonaires (traitement médicamenteux)</term>
<term>Marqueurs biologiques (analyse)</term>
<term>Marqueurs biologiques (sang)</term>
<term>Récepteur-3 au facteur croissance endothéliale vasculaire (sang)</term>
<term>Sirolimus (administration et posologie)</term>
<term>Sirolimus (effets indésirables)</term>
<term>Surveillance pharmacologique ()</term>
<term>Tests de la fonction respiratoire ()</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Enzyme Inhibitors</term>
<term>Hydroxychloroquine</term>
<term>Immunosuppressive Agents</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Hydroxychloroquine</term>
<term>Immunosuppressive Agents</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Biomarkers</term>
<term>Fibrinogen</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Acetyl-CoA Carboxylase</term>
<term>Biomarkers</term>
<term>Vascular Endothelial Growth Factor Receptor-3</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antienzymes</term>
<term>Hydroxychloroquine</term>
<term>Immunosuppresseurs</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Fibrinogène</term>
<term>Marqueurs biologiques</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Lung Diseases</term>
<term>Lymphangioleiomyomatosis</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Lung Diseases</term>
<term>Lymphangioleiomyomatosis</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Lymphangioléiomyomatose</term>
<term>Maladies pulmonaires</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lung Diseases</term>
<term>Lymphangioleiomyomatosis</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Hydroxychloroquine</term>
<term>Immunosuppresseurs</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Monitoring</term>
<term>Drug Therapy, Combination</term>
<term>Respiratory Function Tests</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Acetyl-coA carboxylase</term>
<term>Lymphangioléiomyomatose</term>
<term>Maladies pulmonaires</term>
<term>Marqueurs biologiques</term>
<term>Récepteur-3 au facteur croissance endothéliale vasculaire</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Lymphangioléiomyomatose</term>
<term>Maladies pulmonaires</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Correlation of Data</term>
<term>Female</term>
<term>Humans</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Association de médicaments</term>
<term>Femelle</term>
<term>Humains</term>
<term>Surveillance pharmacologique</term>
<term>Tests de la fonction respiratoire</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We have previously conducted the Sirolimus and Autophagy Inhibition in LAM (SAIL) trial, a phase 1 dose-escalation study of the combination of sirolimus and hydroxychloroquine in patients with lymphangioleiomyomatosis (LAM). The goal of the present study was to analyze sera from the SAIL trial to identify novel biomarkers that could shed light into disease pathogenesis and response to therapy.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30144422</PMID>
<DateCompleted><Year>2019</Year>
<Month>09</Month>
<Day>25</Day>
</DateCompleted>
<DateRevised><Year>2019</Year>
<Month>11</Month>
<Day>01</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1931-3543</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>154</Volume>
<Issue>5</Issue>
<PubDate><Year>2018</Year>
<Month>11</Month>
</PubDate>
</JournalIssue>
<Title>Chest</Title>
<ISOAbbreviation>Chest</ISOAbbreviation>
</Journal>
<ArticleTitle>Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioleiomyomatosis.</ArticleTitle>
<Pagination><MedlinePgn>1070-1082</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0012-3692(18)32243-8</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.chest.2018.08.1029</ELocationID>
<Abstract><AbstractText Label="BACKGROUND">We have previously conducted the Sirolimus and Autophagy Inhibition in LAM (SAIL) trial, a phase 1 dose-escalation study of the combination of sirolimus and hydroxychloroquine in patients with lymphangioleiomyomatosis (LAM). The goal of the present study was to analyze sera from the SAIL trial to identify novel biomarkers that could shed light into disease pathogenesis and response to therapy.</AbstractText>
<AbstractText Label="METHODS">We used the DiscoveryMAP platform from Rules Based Medicine to simultaneously measure 279 analytes in sera collected at each visit from subjects enrolled in the SAIL trial. We used longitudinal regression and pathway analysis to examine analyte rate of change and corresponding effect on lung function and to identify networks and potential nodes of interest.</AbstractText>
<AbstractText Label="RESULTS">A total of 222 analytes were included in the analysis. We identified 32 analytes that changed over the treatment period of the study. Pathway analysis revealed enrichment in cytokine-receptor interaction and mechanistic/mammalian target of rapamycin-related pathways, in addition to seemingly unrelated processes such as rheumatoid arthritis. Search Tool for the Retrieval of Interacting Genes/Proteins analysis identified two hubs centered around acetyl-CoA carboxylase alpha and beta and coagulation factor II. In addition, we identified vascular endothelial growth factor receptor-3 and CCL21 as molecules significantly associated with changes in FEV<sub>1</sub>
 during the study period.</AbstractText>
<AbstractText Label="CONCLUSIONS">We performed a large-scale analyte study in sera of women with LAM and identified potential markers that could be linked to disease pathogenesis, lung injury, and therapeutic response. These data will enable future investigation into the specific roles of these molecules in LAM.</AbstractText>
<AbstractText Label="TRIAL REGISTRY">ClinicalTrials.gov; No. NCT01687179; URL: www.clinicaltrials.gov).</AbstractText>
<CopyrightInformation>Copyright © 2018 American College of Chest Physicians. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lamattina</LastName>
<ForeName>Anthony M</ForeName>
<Initials>AM</Initials>
<AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Taveira-Dasilva</LastName>
<ForeName>Angelo</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Goldberg</LastName>
<ForeName>Hilary J</ForeName>
<Initials>HJ</Initials>
<AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bagwe</LastName>
<ForeName>Shefali</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cui</LastName>
<ForeName>Ye</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Rosas</LastName>
<ForeName>Ivan O</ForeName>
<Initials>IO</Initials>
<AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Moss</LastName>
<ForeName>Joel</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Henske</LastName>
<ForeName>Elizabeth P</ForeName>
<Initials>EP</Initials>
<AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>El-Chemaly</LastName>
<ForeName>Souheil</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Electronic address: sel-chemaly@partners.org.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName>
<AccessionNumberList><AccessionNumber>NCT01687179</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<PublicationTypeList><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2018</Year>
<Month>08</Month>
<Day>23</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Chest</MedlineTA>
<NlmUniqueID>0231335</NlmUniqueID>
<ISSNLinking>0012-3692</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>9001-32-5</RegistryNumber>
<NameOfSubstance UI="D005340">Fibrinogen</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D040321">Vascular Endothelial Growth Factor Receptor-3</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 6.4.1.2</RegistryNumber>
<NameOfSubstance UI="C000588423">ACACA protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 6.4.1.2</RegistryNumber>
<NameOfSubstance UI="D000103">Acetyl-CoA Carboxylase</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>W36ZG6FT64</RegistryNumber>
<NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000103" MajorTopicYN="N">Acetyl-CoA Carboxylase</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000078331" MajorTopicYN="N">Correlation of Data</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016903" MajorTopicYN="N">Drug Monitoring</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005340" MajorTopicYN="N">Fibrinogen</DescriptorName>
<QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="Y">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008171" MajorTopicYN="Y">Lung Diseases</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018192" MajorTopicYN="Y">Lymphangioleiomyomatosis</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012129" MajorTopicYN="N">Respiratory Function Tests</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020123" MajorTopicYN="Y">Sirolimus</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D040321" MajorTopicYN="N">Vascular Endothelial Growth Factor Receptor-3</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">LAM</Keyword>
<Keyword MajorTopicYN="Y">TOR</Keyword>
<Keyword MajorTopicYN="Y">autophagy</Keyword>
<Keyword MajorTopicYN="Y">biomarkers</Keyword>
<Keyword MajorTopicYN="Y">lung function</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year>
<Month>03</Month>
<Day>29</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2018</Year>
<Month>07</Month>
<Day>01</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2018</Year>
<Month>08</Month>
<Day>01</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2018</Year>
<Month>8</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2019</Year>
<Month>9</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2018</Year>
<Month>8</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">30144422</ArticleId>
<ArticleId IdType="pii">S0012-3692(18)32243-8</ArticleId>
<ArticleId IdType="doi">10.1016/j.chest.2018.08.1029</ArticleId>
<ArticleId IdType="pmc">PMC6224706</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Metabolism. 2007 Nov;56(11):1500-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17950100</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nucleic Acids Res. 2017 Jan 4;45(D1):D362-D368</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27924014</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2014 Jul 21;9(7):e103071</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25048611</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2011 Jul 26;108(30):12455-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21746920</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2000 May 23;97(11):6085-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10823953</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Am Thorac Soc. 2012 Jul;9(3):96-101</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22802281</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Histochem Cytochem. 2013 Aug;61(8):580-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23609227</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nucleic Acids Res. 2009 Jan;37(1):1-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19033363</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Autophagy. 2015;11(3):487-502</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25713983</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Signal. 2013 Apr;25(4):829-38</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23291002</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sarcoidosis Vasc Diffuse Lung Dis. 2016 Oct 07;33(3):224-234</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27758987</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Exp Med. 2017 Jul 3;214(7):1925-1935</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28611158</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chest. 2017 Jun;151(6):1302-1310</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28192114</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nucleic Acids Res. 2000 Sep 15;28(18):3442-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10982861</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lupus. 2017 May;26(6):572-579</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27614982</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2013 May 16;121(20):4242-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23476047</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Autophagy. 2012 Jan;8(1):77-87</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22113203</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chest. 2010 Sep;138(3):674-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20382711</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Pathol. 2009 Oct;175(4):1410-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19717640</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 2009 Sep;119(9):2550-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19652365</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2017 Dec 1;199(11):3870-3882</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29070674</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2008 Jan 10;358(2):199-200</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18184970</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2015 Dec 3;163(6):1413-27</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26607793</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Cancer. 2009 May;45(8):1407-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19157860</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Respir Med. 2015 Apr;9(2):195-204</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25757365</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2001 Feb;7(2):199-205</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11175851</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Commun. 2015 Jul 30;6:7888</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26223951</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Pathol. 2017 Jan;187(1):25-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27846380</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Am Thorac Soc. 2017 Jun;14(6):919-928</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28570161</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Rep. 2016 Jun 10;6:27895</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27282818</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2009 Sep 25;284(39):26695-707</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19640849</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Leukoc Biol. 2015 Aug;98(2):173-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26048980</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Res. 2017 Mar 15;77(6):1492-1502</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28202529</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2011 Apr 28;364(17):1595-606</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21410393</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Protoc. 2009;4(1):44-57</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19131956</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 2012 Nov;122(11):3807-16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23114603</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Respir Med. 2013 Aug;1(6):445-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24159565</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Clin Exp Pathol. 2015 Dec 01;8(12):15729-38</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26884842</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Med Rep. 2013 Oct;8(4):1011-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23942837</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur Respir Rev. 2014 Mar 1;23(131):30-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24591659</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Respir Med. 2018 Feb;12(2):95-102</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29171770</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Physiol Lung Cell Mol Physiol. 2015 Dec 15;309(12):L1447-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26432869</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Maryland</li>
<li>Massachusetts</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Massachusetts"><name sortKey="Lamattina, Anthony M" sort="Lamattina, Anthony M" uniqKey="Lamattina A" first="Anthony M" last="Lamattina">Anthony M. Lamattina</name>
</region>
<name sortKey="Bagwe, Shefali" sort="Bagwe, Shefali" uniqKey="Bagwe S" first="Shefali" last="Bagwe">Shefali Bagwe</name>
<name sortKey="Cui, Ye" sort="Cui, Ye" uniqKey="Cui Y" first="Ye" last="Cui">Ye Cui</name>
<name sortKey="El Chemaly, Souheil" sort="El Chemaly, Souheil" uniqKey="El Chemaly S" first="Souheil" last="El-Chemaly">Souheil El-Chemaly</name>
<name sortKey="Goldberg, Hilary J" sort="Goldberg, Hilary J" uniqKey="Goldberg H" first="Hilary J" last="Goldberg">Hilary J. Goldberg</name>
<name sortKey="Henske, Elizabeth P" sort="Henske, Elizabeth P" uniqKey="Henske E" first="Elizabeth P" last="Henske">Elizabeth P. Henske</name>
<name sortKey="Moss, Joel" sort="Moss, Joel" uniqKey="Moss J" first="Joel" last="Moss">Joel Moss</name>
<name sortKey="Rosas, Ivan O" sort="Rosas, Ivan O" uniqKey="Rosas I" first="Ivan O" last="Rosas">Ivan O. Rosas</name>
<name sortKey="Taveira Dasilva, Angelo" sort="Taveira Dasilva, Angelo" uniqKey="Taveira Dasilva A" first="Angelo" last="Taveira-Dasilva">Angelo Taveira-Dasilva</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000115 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000115 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:30144422
   |texte=   Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioleiomyomatosis.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:30144422" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a ChloroquineV1

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021

	Serveur d'exploration Chloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Chloroquine

Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioleiomyomatosis.

Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioleiomyomatosis.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki